| Dr Nazila Eshraghi, DPM | |
|
5 Executive Ct # 102, Clover, SC 29710-9338 | |
| (803) 693-2425 | |
| (833) 989-2166 |
| Full Name | Dr Nazila Eshraghi |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 23 Years |
| Location | 5 Executive Ct # 102, Clover, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164454609 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | E4566 (California) | Secondary |
| 213E00000X | Podiatrist | 718 (South Carolina) | Primary |
| Provider Name | Emad Youssef Dpm Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1194331132 PECOS PAC ID: 8224457502 Enrollment ID: O20201006002371 |
News Archive
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided "100% protection against a lethal dose of the Ebola virus" in a recent animal study published in The Journal of Infectious Diseases.
When researchers compared the stools of 40 infants who were exclusively breastfed with those of 13 who were exclusively formula fed, the average daily stool frequency was significantly higher in the breastfed than formula fed infants during the first month of life (4.9 versus 2.3) and second month of life (3.2 versus 1.6).
BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C.
Anaplastic thyroid cancer is a rare form of thyroid tumor, but it is also the most deadly. Newly developed evidence-based recommendations for the diagnosis, treatment, and long-term monitoring and follow-up care of patients with this extremely aggressive form of thyroid cancer are published in Thyroid, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nazila Eshraghi, DPM 5 Executive Ct # 102, Clover, SC 29710-9338 Ph: (803) 693-2425 | Dr Nazila Eshraghi, DPM 5 Executive Ct # 102, Clover, SC 29710-9338 Ph: (803) 693-2425 |
News Archive
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided "100% protection against a lethal dose of the Ebola virus" in a recent animal study published in The Journal of Infectious Diseases.
When researchers compared the stools of 40 infants who were exclusively breastfed with those of 13 who were exclusively formula fed, the average daily stool frequency was significantly higher in the breastfed than formula fed infants during the first month of life (4.9 versus 2.3) and second month of life (3.2 versus 1.6).
BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C.
Anaplastic thyroid cancer is a rare form of thyroid tumor, but it is also the most deadly. Newly developed evidence-based recommendations for the diagnosis, treatment, and long-term monitoring and follow-up care of patients with this extremely aggressive form of thyroid cancer are published in Thyroid, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
› Verified 8 days ago